Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNet

$484,637U01FY2013DKNIH

Vanderbilt University, Nashville TN

Investigators

Linked publications & trials

Paper 39670998 Paper 39167668 Paper 39137044 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34850014 Paper 34642772 Paper 34620616 Paper 34551936 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32844178 Paper 32833543 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31794865 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30552135 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30061316 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29429978 Paper 29171129 Paper 29164254 Paper 29040630 Paper 29025879 Paper 28956083 Paper 28860125 Paper 28821222 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28520980 Paper 28500393 Paper 28226181 Paper 28202550 Paper 27704166 Paper 27655844 Paper 27579340 Paper 27456836 Paper 27422577 Paper 27385327 Paper 27362539 Paper 27208341 Paper 27143290 Paper 27114212 Paper 26995649 Paper 26991969 Paper 26991448 Paper 26895885 Paper 26822082 Paper 26692253 Paper 26676824 Paper 26642366 Paper 26633480 Paper 26578518 Paper 25773405 Paper 25758770

Abstract

DESCRIPTION (provided by applicant): In Response to RFA DK-08-011, Vanderbilt University, a TrialNet Major Affiliate since 2006, proposes to become a Clinical Center. William E. Russell, MD, TrialNet PI, will continue in that role. He is joined by James W. Thomas MD, as the Co-Investigator. Salient points of this proposal: (Vanderbilt became an active Major Affiliate (MA) of TrialNet in October, 2006, 28 months ago. With the modest resources of a MA we have recruited 591 subjects from 12 states into the Natural History Study; enrolled 2 subjects into the Oral Insulin Prevention Trial, and four subjects into the CTLA4-lg study. We are the only MA to engage in this intervention study. We have also recruited 433 subjects from 51 families into the T1 Diabetes Genetics Consortium, making us the leading T1DGC recruitment site internationally. (We document an strong institutional support for the goals and activities of TrialNet, including: a commitment by Dr. Jonathan Gitlin, Chair of Pediatrics to fund an additional 1.0 FTE of TrialNet study coordinator; the strong endorsement of Dr. Gordon Bernard Director of the CTSA offering the full services of the CRCs; and a commitment by Dr. Alvin Powers to expand dedicated space in the VEDC, provide 0.5 FTE of administrative support, and the full resources of the Vanderbilt Diabetes Center for TrialNet. (The investigators are highly experienced and well-suited to carrying out the aims of a TrialNet Clinical Center. With the input of a Vanderbilt TrialNet Scientific Advisory Committee, they propose a diabetes intervention trial Combined inflammatory blockade and oral tolerance for intervention in T1D. (New strategies and alliances are proposed to facilitate recruitment to TrialNet studies at the level of a Clinical Center. Among them are partnerships with the TN Department of Healt and other instutitions with a far reach into our region. A Remote Recruitment Program and possible Mibile Clinical Research Unit are proposed to take our screening activities far beyond middle TN. (A TrialNet Community Advisory Board has been established to secure input regarding screening and outreach strategies from a variety of diabetes stakeholders in our region.

View original record on NIH RePORTER →